false Q3 --07-31 0000720762 0000720762 2024-08-01 2025-04-30 0000720762 2025-06-11 0000720762 2025-04-30 0000720762 2024-07-31 0000720762 us-gaap:RelatedPartyMember 2025-04-30 0000720762 us-gaap:RelatedPartyMember 2024-07-31 0000720762 us-gaap:SeriesBPreferredStockMember 2025-04-30 0000720762 us-gaap:SeriesBPreferredStockMember 2024-07-31 0000720762 2025-02-01 2025-04-30 0000720762 2024-02-01 2024-04-30 0000720762 2023-08-01 2024-04-30 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-07-31 0000720762 us-gaap:CommonStockMember 2024-07-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0000720762 us-gaap:RetainedEarningsMember 2024-07-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-10-31 0000720762 us-gaap:CommonStockMember 2024-10-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0000720762 us-gaap:RetainedEarningsMember 2024-10-31 0000720762 2024-10-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-01-31 0000720762 us-gaap:CommonStockMember 2025-01-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0000720762 us-gaap:RetainedEarningsMember 2025-01-31 0000720762 2025-01-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-07-31 0000720762 us-gaap:CommonStockMember 2023-07-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0000720762 us-gaap:RetainedEarningsMember 2023-07-31 0000720762 2023-07-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-10-31 0000720762 us-gaap:CommonStockMember 2023-10-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0000720762 us-gaap:RetainedEarningsMember 2023-10-31 0000720762 2023-10-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-01-31 0000720762 us-gaap:CommonStockMember 2024-01-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0000720762 us-gaap:RetainedEarningsMember 2024-01-31 0000720762 2024-01-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-08-01 2024-10-31 0000720762 us-gaap:CommonStockMember 2024-08-01 2024-10-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-08-01 2024-10-31 0000720762 us-gaap:RetainedEarningsMember 2024-08-01 2024-10-31 0000720762 2024-08-01 2024-10-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-11-01 2025-01-31 0000720762 us-gaap:CommonStockMember 2024-11-01 2025-01-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-01-31 0000720762 us-gaap:RetainedEarningsMember 2024-11-01 2025-01-31 0000720762 2024-11-01 2025-01-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-02-01 2025-04-30 0000720762 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0000720762 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0000720762 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-08-01 2023-10-31 0000720762 us-gaap:CommonStockMember 2023-08-01 2023-10-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2023-08-01 2023-10-31 0000720762 us-gaap:RetainedEarningsMember 2023-08-01 2023-10-31 0000720762 2023-08-01 2023-10-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-11-01 2024-01-31 0000720762 us-gaap:CommonStockMember 2023-11-01 2024-01-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2023-11-01 2024-01-31 0000720762 us-gaap:RetainedEarningsMember 2023-11-01 2024-01-31 0000720762 2023-11-01 2024-01-31 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-02-01 2024-04-30 0000720762 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-04-30 0000720762 us-gaap:RetainedEarningsMember 2024-02-01 2024-04-30 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-04-30 0000720762 us-gaap:CommonStockMember 2025-04-30 0000720762 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0000720762 us-gaap:RetainedEarningsMember 2025-04-30 0000720762 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-04-30 0000720762 us-gaap:CommonStockMember 2024-04-30 0000720762 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0000720762 us-gaap:RetainedEarningsMember 2024-04-30 0000720762 2024-04-30 0000720762 us-gaap:CommonStockMember 2024-08-01 2025-04-30 0000720762 us-gaap:CommonStockMember 2023-08-01 2024-04-30 0000720762 NIMU:FrostGammaInvestmentsTrustMember 2025-04-30 0000720762 NIMU:FrostGammaInvestmentsTrustMember 2024-07-31 0000720762 NIMU:DrJaneHsiaoMember 2025-04-30 0000720762 NIMU:DrJaneHsiaoMember 2024-07-31 0000720762 NIMU:FrostGammaInvestmentsTrustMember 2024-08-01 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2021-07-31 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2022-07-31 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2024-08-01 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2023-08-15 2023-08-15 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2023-08-15 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2025-01-01 2025-03-31 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaInvestmentsTrustMember 2025-03-31 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaMember 2024-08-01 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:FrostGammaMember 2023-08-01 2024-07-31 0000720762 NIMU:FrostGammaMember 2025-04-30 0000720762 NIMU:FrostGammaMember 2024-07-31 0000720762 NIMU:DrJaneHsiaoMember 2024-08-01 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:DrJaneHsiaoMember 2021-07-31 0000720762 NIMU:PromissoryNoteMember NIMU:DrJaneHsiaoMember 2022-07-31 0000720762 NIMU:PromissoryNoteMember NIMU:DrJaneHsiaoMember 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:DrJaneHsiaoMember 2024-08-01 2025-04-30 0000720762 NIMU:PromissoryNoteMember NIMU:DrJaneHsiaoMember 2023-08-01 2024-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC. 20549

FORM 10-Q

(Mark One)

☒	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended April 30, 2025

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from _______________ to ____________________

Commission File Number 000-13176

NON-INVASIVE MONITORING SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Florida

59-2007840

(State or other jurisdiction of

incorporation or organization)

(I.R.S. employer

identification no.)

4400 Biscayne Blvd., Miami, Florida 33137

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (305) 575-4200

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock $0.01 par value per share		NIMU		OTC Pink

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

154,810,655 shares of the Company’s common stock, par value $0.01 per share, were outstanding as of June 11, 2025.

NON-INVASIVE MONITORING SYSTEMS, INC.

TABLE OF CONTENTS FOR FORM 10-Q

PART I. FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS (unaudited)

	Condensed Consolidated Balance Sheets as of April 30, 2025 and July 31, 2024	3

	Condensed Consolidated Statements of Operations for the three and nine months ended April 30, 2025 and 2024	4

	Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the three and nine months ended April 30, 2025 and 2024	5

	Condensed Consolidated Statements of Cash Flows for the nine months ended April 30, 2025 and 2024	6

	Notes to Condensed Consolidated Financial Statements	7

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	11

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	12

ITEM 4.	CONTROLS AND PROCEDURES	12

PART II. OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	14

ITEM 1A.	RISK FACTORS	14

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	14

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	14

ITEM 4.	MINE SAFETY DISCLOSURES	14

ITEM 5.	OTHER INFORMATION	14

ITEM 6.	EXHIBITS	14

	SIGNATURES	15

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	April 30, 2025			July 31, 2024
		(Unaudited)
ASSETS
Current assets
Cash	$	16		$	25
Prepaid expenses and other current assets		9			9
Total current assets		25			34

Total assets	$	25		$	34

LIABILITIES AND SHAREHOLDERS’ DEFICIT

Current liabilities
Accounts payable and accrued expenses	$	121		$	110
Current liabilities – discontinued operations		51			51
Notes payable – related parties		595			-
Accrued interest – related parties		144			-
Total current liabilities		911			161

Notes payable – related parties		-			500
Accrued interest – related parties		-			98

Total liabilities		911			759

Commitments and contingencies		-			-

Shareholders’ deficit
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10 per share		-			-
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding as of April 30, 2025 and July 31, 2024		1,548			1,548
Additional paid in capital		26,574			26,574
Accumulated deficit		(29,008	)		(28,847	)

Total shareholders’ deficit		(886	)		(725	)
Total liabilities and shareholders’ deficit	$	25		$	34

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Unaudited

(In thousands, except per share data)

	2025			2024			2025			2024
	Three months ended April 30,						Nine months ended April 30,
	2025			2024			2025			2024
Operating costs and expenses
General and administrative	$	26		$	30		$	115		$	146

Total operating costs and expenses		26			30			115			146

Operating loss		(26	)		(30	)		(115	)		(146	)

Interest expense – related parties		(16	)		(14	)		(46	)		(40	)

Net loss	$	(42	)	$	(44	)	$	(161	)	$	(186	)

Weighted average number of common shares outstanding - Basic and diluted		154,811			154,811			154,811			154,811

Basic and diluted loss per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT - Unaudited

For the three, six and nine months ended April 30, 2025 and 2024

(In thousands, except share amounts)

	Shares		Amount		Shares		Amount		Capital		Deficit			Total
	Series B				Common Stock				Additional Paid in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total

Balance at July 31, 2024		100	$	-		154,810,655	$	1,548	$	26,574	$	(28,847	)	$	(725	)
Net loss		-		-		-		-		-		(77	)		(77	)
Balance at October 31, 2024		100		-		154,810,655		1,548		26,574		(28,924	)		(802	)
Net loss		-		-		-		-		-		(42	)		(42	)
Balance at January 31, 2025		100		-		154,810,655		1,548		26,574		(28,966	)		(844	)
Net loss		-		-		-		-		-		(42	)		(42	)
Balance at April 30, 2025		100	$	-		154,810,655	$	1,548	$	26,574	$	(29,008	)	$	(886	)

	Series B				Common Stock				Additional Paid in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total

Balance at July 31, 2023		100	$	-		154,810,655	$	1,548	$	26,574	$	(28,734	)	$	(612	)
Net loss		-		-		-		-		-		(88	)		(88	)
Balance at October 31, 2023		100		-		154,810,655		1,548		26,574		(28,822	)		(700	)
Net loss		-		-		-		-		-		(54	)		(54	)
Balance at January 31, 2024		100		-		154,810,655		1,548		26,574		(28,876	)		(754	)
Balance		100		-		154,810,655		1,548		26,574		(28,876	)		(754	)
Net loss		-		-		-		-		-		(44	)		(44	)
Balance at April 30, 2024		100	$	-		154,810,655	$	1,548	$	26,574	$	(28,920	)	$	(798	)
Balance		100	$	-		154,810,655	$	1,548	$	26,574	$	(28,920	)	$	(798	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Unaudited

(In thousands)

Nine months ended April 30, 2025 and 2024

	2025			2024
Operating activities
Net loss	$	(161	)	$	(186	)
Adjustments to reconcile net loss to net cash used in operating activities
Changes in operating assets and liabilities

Accounts payable and accrued expenses		11			2
Accrued interest – related parties		46			41
Net cash used in operating activities		(104	)		(143	)

Financing Activities
Proceeds from notes payable – related parties		95			200
Net cash provided by financing activities		95			200

Net increase (decrease) in cash		(9	)		57
Cash, beginning of period		25			7
Cash, end of period	$	16		$	64

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NON-INVASIVE MONITORING SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

For the Three and Nine months ended April 30, 2025 and 2024

The following (a) condensed consolidated balance sheet at July 31, 2024 was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements, and (b) the unaudited condensed consolidated interim financial statements included herein have been prepared by Non-Invasive Monitoring Systems, Inc. (together with its consolidated subsidiaries, the “Company” or “NIMS”) in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the quarterly report on Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of April 30, 2025, and results of operations and cash flows for the interim periods ended April 30, 2025 and 2024. The results of operations for the three and nine months ended April 30, 2025, are not necessarily indicative of the results for a full year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The Company’s accounting policies continue unchanged from July 31, 2024. These financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended July 31, 2024.

1. ORGANIZATION AND BUSINESS

Organization. Non-Invasive Monitoring Systems, Inc., a Florida corporation (together with its consolidated subsidiaries, the “Company” or “NIMS”). The Company previously developed and marketed its Exer-Rest^®line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology of which the Company maintains patents. The Company maintains limited administration, but does not have any operations or inventory.

Business. The Company is currently a shell company (as defined in Rule 12b-2 of the Exchange Act).

Discontinued Operations. On May 3, 2019, the Company exchanged inventory for forgiveness of accrued unpaid rent. The Company has no inventory, no immediate plans to replenish inventory and has no current plans to develop or market new products.

Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at April 30, 2025 and July 31, 2024.

Going Concern. The Company’s condensed consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying condensed consolidated financial statements, the Company had net losses of approximately $161,000 and $186,000 for the nine months ended April 30, 2025 and 2024, respectively, and has experienced continuous cash outflows from operating activities. The Company also has an accumulated deficit of approximately $29,008,000 as of April 30, 2025. The Company had approximately $16,000 of cash at April 30, 2025 and a shareholders’ deficit of approximately $886,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company is seeking potential mergers, acquisitions and strategic collaborations. The Company is also exploring obtaining additional promissory notes from related parties. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All inter-company accounts and transactions have been eliminated in consolidation.

Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. At April 30, 2025 and July 31, 2024, the Company had no cash equivalents.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions, such as deferred taxes and accruals as estimates, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ materially from these estimates.

Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of April 30, 2025 and July 31, 2024. The respective carrying value of certain on-balance-sheet financial instruments such as cash, prepaid expenses, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.

Related Parties. The Company follows ASC 850 “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions.

Recent Accounting Pronouncements. The Company considers the applicability and impact of all relevant recently adopted Accounting Standard Updates (“ASU’s”). Our conclusion was that they did not have any material effect on the condensed consolidated financial statements going foward.

3. SHAREHOLDERS’ DEFICIT

The Company has a single class of Preferred Stock. Holders of Series B Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. We are currently authorized to issue an aggregate of 401,000,000 shares of capital stock, consisting of 400,000,000 shares of common stock and 1,000,000 designated shares of preferred stock with preferences and rights to be determined by our Board of Directors, of which 100 shares have been designated as Series B.

Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared.

No preferred stock dividends were declared for the three and nine months ended April 30, 2025 and 2024.

The Company did not issue any shares of the Company’s common stock during the three and nine months ended April 30, 2025 and 2024.

4. BASIC AND DILUTED LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. In computing diluted net loss per share for the periods ended April 30, 2025 and 2024, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed conversion of preferred stock would be anti-dilutive.

5. RELATED PARTY TRANSACTIONS

The Company is provided office space in Miami, Florida on a month-to-month basis by a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. For the six months ended January 31, 2025 and 2024, the Company did not record any rent expense related to the Miami lease. At April 30, 2025 and 2024 there was no rent payable.

The Company’s Chief Financial Officer serves as the Chief Financial Officer and Co-Chief Executive Officer of Cocrystal Pharma, Inc., a clinical stage Nasdaq listed biotechnology company, and in which Dr. Frost serves on the Board.

See Note 6 for notes payable to related parties.

6. NOTES PAYABLE – RELATED PARTIES

Notes payable- related party are summarized in the following table (in thousands):

	As of April 30, 2025		As of July 31, 2024

(a) Notes payable - Frost Gamma Investments Trust	$	445	$	350
(b) Notes payable - Dr. Jane Hsiao		150		150
Total Notes payable - related party	$	595	$	500

(a) The Company has outstanding notes payable to Frost Gamma Investments Trust (“Frost Gamma”) which pertained to promissory notes issued in fiscal 2021 and 2022, in the principal amount of $75,000 and $75,000, respectively. The promissory notes accrue interest at a rate of 11% per annum, payable on the maturity date on July 31, 2025, as amended on August 15, 2023. The Frost Gamma promissory note may be prepaid in advance of the maturity date without penalty. Frost Gamma is a trust controlled by Dr. Phillip Frost, a current director of the Company, and who beneficially owns in excess of 10% of the Company’s common stock.

On August 15, 2023, the Company entered into a new promissory note agreement with Frost Gamma in the principal amount of $200,000, which also accrues interest at a rate of 11% per annum, payable on the maturity date on July 31, 2025. This promissory note may also be prepaid in advance of the maturity date without penalty.

On September 25, 2024, October 23, 2024 and January 23, 2025, the Company entered into new promissory note agreements with Frost Gamma in the aggregate principal amount of $95,000, which also accrues interest at a rate of 11% per annum, payable on the maturity date on July 31, 2025. The promissory notes may also be prepaid in advance of the maturity date without penalty.

There were no payments made on the promissory notes to Frost Gamma and as such, total outstanding notes payable balance was $445,000 as of April 30, 2025 and $350,000 as of July 31, 2024.

(b) The Company has outstanding notes payable Jane Hsiao, Ph.D. (“Dr. Hsiao”) which pertained to promissory notes issued in fiscal 2021 and 2022, in the principal amount of $75,000 and $75,000, respectively. The promissory notes accrue interest at a rate of 11% per annum, payable on the maturity date on July 31, 2025, as amended on August 15, 2023. The promissory notes to Dr. Hsiao may be prepaid in advance of the maturity date without penalty. Dr. Hsiao is the Company’s Chairman and Interim CEO, and who beneficially owns in excess of 10% of the Company’s common stock.

There were no payments made on the promissory notes to Dr. Hsiao and as such, total outstanding notes payable balance was $150,000 as of April 30, 2025 and July 31, 2024.

7. COMMITMENTS AND CONTINGENCIES

Leases.

The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month-to-month basis at no cost.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Cautionary Statement Regarding Forward-looking Statements.

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements regarding Non-Invasive Monitoring Systems, Inc. (the “Company” or “NIMS,” also referred to as “us”, “we” or “our”). These forward-looking statements represent our expectations or beliefs concerning the Company’s financial condition, business strategies, and other information and that involve substantial risks and uncertainties. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. The Company’s actual results of operations, some of which are beyond the Company’s control, could differ materially from the activities and results implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the Company’s: history of operating losses and accumulated deficit; need for additional financing; dependence on management; risks related to proprietary rights; other factors described herein as well as the factors contained in “Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended July 31, 2024. We do not undertake any obligation to update forward-looking statements, except as required by applicable law. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

Overview

We previously were engaged in the development, manufacture and marketing of non-invasive, whole body periodic acceleration (“WBPA”) therapeutic platforms, which are motorized platforms that move a subject repetitively head to foot. The Company discontinued operations in May 2019; accordingly, certain liabilities are classified as discontinued operations.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to income taxes. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Consolidated Financial Statements set forth in Item 1 of this Report on Form 10-Q.

While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.

Results of Operations

We have discontinued operations in May 2019. The Company is assessing potential mergers, acquisitions, strategic collaborations and liquidation.

Three and Nine months ended April 30, 2025 Compared to Three and Nine months ended April 30, 2024

General and administrative costs and expenses. General and administrative (“G&A”) costs and expenses from continuing operations were $26,000 and $115,000 for the three and nine months ended April 30, 2025, respectively, as compared to $30,000 and $146,000 for the three and nine months ended April 30, 2024, respectively. The $4,000 decrease for the three months ended was primarily due to timing of expenses and $31,000 decrease for the nine months ended was primarily due to fees for professional services and insurance expense.

Interest expense – related parties. Interest expense was $16,000 and $46,000 for the three and nine months ended April 30, 2025, respectively, as compared to $14,000 and $40,000 for the three and nine months ended April 30, 2024. The interest expense is related to the Promissory Notes described in Note 6 to the accompanying unaudited condensed consolidated financial statements.

Net loss. Net loss was $42,000 and $161,000 for the three and nine months ended April 30, 2025, respectively, as compared to $44,000 and $186,000 for the three and nine months ended April 30, 2024, respectively. The $2,000 and $25,000 decrease for the three and nine months ended April 30, 2025, respectively, was primarily due to a reduction in professional fees and insurance expense.

Going Concern. The Company’s condensed consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying condensed consolidated financial statements, the Company had net losses of approximately $161,000 and $186,000 for the nine months ended April 30, 2025 and 2024, respectively, and has experienced continuous cash outflows from operating activities. The Company also has an accumulated deficit of approximately $29,008,000 as of April 30, 2025. The Company had approximately $16,000 of cash at April 30, 2025 and negative working capital deficit of approximately $886,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

Liquidity and Capital Resources

The Company’s operations have been primarily financed through private sales of its equity securities and advances under Credit Facility and Promissory Notes. At April 30, 2025, we had approximately $16,000 of cash and a shareholders’ deficit of approximately $886,000. We believe that the cash on hand at April 30, 2025 is not sufficient to meet our anticipated cash requirements for the next 12 months.

We expect to incur losses for the foreseeable future. It is likely that we will be required to obtain additional external financing through public or private equity offerings, debt financings from shareholders or collaborative agreements. No assurance can be given that such additional financing will be available on acceptable terms or at all.

Current economic conditions have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital in a timely manner. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders.

Net cash used in operating activities was $104,000 and $143,000 for nine months ended April 30, 2025 and 2024, respectively. This $39,000 decrease was primarily due to a reduction in professional fees and timing of expenses.

Net cash provided by financing activities was $95,000 and $200,000 for nine months ended April, 2024 and 2024, respectively. This was primarily due to the proceeds from Promissory Notes described in Note 6 to the accompanying unaudited condensed consolidated financial statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not required for smaller reporting companies as defined in Rule 12b-2 of the Exchange Act.

ITEM 4.

CONTROLS AND PROCEDURES.

The Company’s management, with the participation of its Interim Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) or 15d-15(e)) as of April 30, 2025. Based upon that evaluation, the Interim Chief Executive Officer and Chief Financial Officer concluded that, as of that date, the Company’s disclosure controls and procedures were not effective due to the material weakness identified below.

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of April 30, 2025, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

Process and procedures – The Company does not employ a sufficient number of individuals to maintain optimal segregation of duties. The internal control procedures over the completeness and accuracy of the general ledger information and the risk assessment process are not formally documented and may not be designed and operate with a level of precision adequate to prevent or detect misstatements. Since internal control procedures are not formally documented, management cannot monitor their effectiveness.

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of April 30, 2025 based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Notwithstanding the existence of these material weaknesses in the Company’s internal control over financial reporting, the Company’s management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the year ended July 31, 2024 filed with the SEC on October 25, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

During the three months ended April 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as such terms are defined in Item 408 of Regulation S-K

Item 6. Exhibits

	31.1	Certification of Chief Executive Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.

	31.2	Certification of Chief Financial Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.

	32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906of the Sarbanes-Oxley Act of 2002.

	101.INS	Inline XBRL Instance Document*

	101.SCH	Inline XBRL Taxonomy Extension Schema Document*

	101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document*

	101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document*

	101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document*

	101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document*

	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

NON-INVASIVE MONITORING SYSTEMS, INC

April 30, 2025

SIGNATURES

In accordance with the requirements of the Exchange Act the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 13, 2025	By:	/s/ Jane H. Hsiao
		Jane H. Hsiao, Interim Chief Executive Officer

Dated: June 13, 2025	By:	/s/ James J. Martin
		James J. Martin, Chief Financial Officer

INDEX TO EXHIBITS

31.1	Certification of Chief Executive Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.

31.2	Certification of Chief Financial Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.

32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906of the Sarbanes-Oxley Act of 2002.

101.INS	Inline XBRL Instance Document*

101.SCH	Inline XBRL Taxonomy Extension Schema Document*

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document*

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document*

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

NON INVASIVE MONITORING SYSTEMS INC /FL/ 10-Q